Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

Authors :: Van Der Heijden, Michiel Simon
Powles, Thomas
Gupta, Shilpa
Bedke, Jens
Kikuchi, Eiji
De Wit, Ronald
Galsky, Matt D.
Duran, Ignacio
Necchi, Andrea
Retz, Margitta
Yu, Evan Y.
Hoffman-Censits, Jean H.
Iyer, Gopa
Park, Se Hoon
Su, Wen-Pin
Parmar, Hema
Guan, Xuesong
Gorla, Seema Rao
Homet Moreno, Blanca
Valderrama, Begoña Pérez
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pLBA530-LBA530, 6p
Publication Year :: 2024

Full Text Access

Tools